Inactivation of model viruses suspended in fresh frozen plasma using novel methylene blue based device

Ameneh Elikaei¹, Zohreh Sharifi²*, Seyed Masoud Hosseini¹, Hamid Latifi³, Mir Kamaran Musavi Hosseini²

¹Department of Microbiology, Faculty of Biological Science Shahid Beheshti University GC, Tehran, Iran. ²Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. ³Laser and Plasma Research Institute, Shahid Beheshti University, GC, Tehran, Iran.

Received: August 2013, Accepted: October 2013.

ABSTRACT

Background and Objective: There is a concern on safety of human Fresh Frozen Plasma (FFP) as it is a source of some medicinal products. The possibility of transmission of blood-borne are reported often due to emerging viruses. There are some Pathogen Reduction Technologies (PRT) to inactivate viruses. Methylene Blue (MB) based method is one of them. The aim of this study was to examine new designated device to inactivate model viruses.

Materials and Methods: Four model viruses were used in this study: Vesicular stomatitis virus (VSV), Herpes Simplex Virus I (HSV-1), Bovine Viral Diarrhea Virus (BVDV) and Polio Virus. 50% Tissue Culture Infective Dose (TCID 50) and Reed–Muench Methods were used to titer the viruses. MB in two final concentration of 0.1 µM and 1 µM and illumination in about 627 nm with red LED (Lamp Emitting Diode) for 15, 30, 45 and 60 minutes were used. Three replicates employed for each experiments.

Results: 1 µM concentration of MB showed more effective than 0.1 µM in all designed illumination period for inactivation of HSV, VSV and BVDV. This method also demonstrated best results for enveloped model viruses. The most Log reduction for HSV, VSV and BVDV were 6.28, 5.54 and 6.22, respectively. For HSV and BVDV inactivation, the best illumination period was 45 minutes.

Conclusion: Model viruses showed sensitivity combination of MB and illumination using red LEDs. As results show this device could inactivate model viruses and reduce their titer very close to approved commercial devices, in compare.

Keywords: Blood-borne Viruses, Methylene Blue, Red LED, Fresh Frozen Plasma

INTRODUCTION

Human Fresh Frozen Plasma (FFP) is a source of wide range of medicinal products and there is a concern on its safety (1). The risk of transfusion-transmitted blood-borne viruses today is lower than ever, due to donor selection criteria and blood-donor testing (2). However, the supply of blood products remain subject to contamination with known and yet to identify human pathogens (3).

Several different approaches have been undertaken to reduce or prevent transmitting blood-borne pathogens in Fresh Frozen Plasma (FFP). The most effective pathogen reduction methods that currently available for FFP involved the use of Solvent Detergent (SD), Methylene Blue (MB), amotosalen and riboflavin as additives (4).

The appropriate method should remove or inactivate pathogens, including emerging pathogens, without damaging the function or longevity of blood
products. In addition, they should be free from toxic and immunogenic components (5). MB is a phenothiazine compound that in conjunction with photo could inactivate selective biologics (6). MB based Pathogen Reduction Technologies (PRT) have some advantages, particularly lack of plasma pooling, i.e. recipients would receive plasma from individual donations rather than from a plasma pool (7). Methylene blue in combination with light treatment FFP (MBLT-plasma) has been followed by at least three different protocols (8); Spring protocol (9), and two different protocols from Macopharma® (10).

The aim of this study was to evaluate the ability of novel device using MB in combination with red LED for inactivation of model viruses suspended in FFP.

MATERIAL AND METHODS

Device designation. 143pcs (pieces) of 1WredLED (Lamp Emission Diodes) lamp have been used on the device to emit light with central wave length of 627 nm and 20 nm width (FWHM full width at half maximum). Two sides pouches irradiated simultaneously. The distance of the middle of the bag from LED arrays source was 4.5cm. This device was designed for light (LED) employing simulation software Wolfram Mathematica® considering the intensity profile. LED sand right number of used LEDs. Light emission to the FFP bag was adjusted and uniformed. A control Centre designed for temperature and exposure.

Fresh Frozen Plasma (FFP). O+FFP were obtained from Iranian Blood Transfusion Centre (IBTO). These samples examined to be free from Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV). They Aliquots into 50 ml plasma universal bags (JMS Co.,) and stored at -20ºC.

Methylene blue. MB was obtained from Merck (Cat. No. 1592700010). Final concentration of MB in 50 ml of FFP adjusted to be 0.1 and 1 µM concentration. The dye solution was stored in dark at 4°C before use (11).

Preparation and quantification of model viruses. 4 model viruses were used to evaluate new designated device, including enveloped viruses; Bovine Viral Diarrhea Virus (BVDV; Flaviviridae, Pestivirus, Nadal strain) a surrogate for HCV, Herpes Simplex Virus (HSV; Herpesviridae, Alpha herpes virinae, Herpes Simplex Virus, Type I) and Vesicular Stomatitis Virus (VSV; Rhabdoviridae, Vesiculovirus, Indian strain) models for HBV and HIV, respectively, and also one non- Enveloped virus, Polio (Picornaviridae, Enterovirus, Sabin vaccine). Model viruses’ selection was based on WHO guideline (12) and obtained from Research Centre of Iranian Blood Transfusion Organization (IBTO), Department of Virology (12).

Model viruses were propagated in different cell lines; BVDV in Bovine Kidney (BK), HSV and VSV in Vero (African Green Monkey Kidney) and Polio in HeLa (Human Carcinoma Cervix) cell lines (National Cell Bank of Iran, Iran Pasteur Institute, NCBI Nos. C500, C101 and C115, respectively). All cell lines were grown in Dulbecco Modified Eagle’s Medium (DMEM) with 10% fetal calf serum with penicillin- streptomycin antibiotics (Gibco, UK) as antibiotics. The antibiotics were used in 1% of final concentration. They incubated at 37°C with 5% CO2. Confluent monolayers of each cell type were grown in sterile T25 flasks (SPL, Korea) and inoculated with 0.5 ml of the model viruses. Upon Cytopathic Effect (CPE) completion, they harvested and then stored at -80°C for 24 h followed by filtration of supernatant through 0.45 µ nitrocellulose filter (Biofil). Filtered solution stored at -80°C for further virus titration in 96-well flat-bottom sterile plate using 50% Tissue Culture Infectivity Dose (TCID 50) method. Reed-Muench method used for calculation of virus titer.

Inactivation methods. Each bag that contains 50 ml FFP was spiked with, 5 ml of prepared stock virus. Two different concentration of MB (0.1 and 1 µM) and 4 different illumination periods for each model virus were used: 15, 30, 45 and 60 minutes. Each assay repeated 3 times. Several controls were examined that including FFP with model virus; FFP with model virus & MB without illumination; and FFP with model virus & Illumination without MB. 1 ml of each sample was used to calculate virus titer using TCID 50 and Reed and Muench calculation method. All cell cultures in flat-bottom sterile 96 well-titer plates were studied microscopically for the presence of CPE. Quantitative infectivity assays were performed using the end-point titration methods, TCID 50. Each well observed daily for positive or negative for CPE. The final results were converted to aTCID 50 / ml (13).
**METHYLENE BLUE AND IRRADIATION FOR VIRUS INACTIVATION**

**RESULTS**

MB without illumination and 1h illumination without MB showed no significant effects on virus titers \((p > 0.05)\). 1 µM concentration of MB had significantly more effective than 0.1 µM in each illumination exposure time in HSV, VSV and BVDV. This method demonstrated the best results for enveloped viruses and most Log reduction for HSV, VSV and BVDV viruses; 6.28, 5.54 and 6.22, respectively. For HSV and BVDV inactivation, the best illumination periods was 45 minutes (Table 1 & 2). CPE of model viruses before and after of using MB and irradiation is shown in Fig. 1.

**DISCUSSION**

Donor FFP are tested in some countries for the presence of some pathogens prior to administration, nevertheless, small finite risk of transmission of infectious agent’s majority due to window period and emerging viruses still bearing potential risk factor (14-16). Several new technologies have been developed to reduce blood transfusion risks. MB based technologies are categorized in 3 main protocols. In this study, a new pathogen device was designed to reduce viruses. These new device used red LEDs from two sides to inactivate pathogens, so its exposure time reduced. It caused cost and time benefits and led to maintain FFP proteins in acceptable range.

As results showed, this new device is effective for enveloped viruses (HSV, VSV, and BVDV) and could reduce virus titer near to WHO recommendations but it is not appropriate for non-enveloped viruses (such as poliovirus with < Log 10² reduction). HSV and VSV are enveloped, but BVDV is a non-enveloped virus.

---

**Table 1.** Inactivation of Model viruses using 1 µM concentration of MB and different illumination period \((n = 3)\).

| Model Virus (Mean titer) | Exposure Time (minutes) | Energy J/cm² | HSV  | VSV  | BVDV | Polio |
|-------------------------|-------------------------|--------------|------|------|------|-------|
|                         |                         |              | \(10^{7.28}\) | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| Initial titer           | 0                       | 0            | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| FFP sample: 0 min       | 0                       | 0            | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 15 min                  | 27                      | 10⁴-28       | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 30 min                  | 54                      | 10⁴-28       | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 45 min                  | 81                      | 0.0*         | \(10^{7.66}\) | \(10^{7.22}\) | \(0.0*\) |
| 60 min                  | 108                     | 0.0*         | \(10^{7.66}\) | \(10^{7.22}\) | \(0.0*\) |

*NO CPE observed in any well

**FFP proteins quality.** 4 FFP proteins selected to measure their concentration in FFP sample before and after pathogen inactivation to determine FFP quality. Factors V (STA®-Deficient V REF 00744), and VIII (STA®-Deficient VIII REF 00725), also Fibrinogen (STA®-Fibrinogen REF 00674) and Antithrombin inactivity (STA®-Stachrom® AT III REF 00672) (Stago®, France) were measured.

**Statistics.** SPSS 16.00 and ANOVA were employed for data analysis.

4 FFP proteins selected to measure their activity before and after 30 min illumination in 1 µM concentration of MB. Fibrinogen had the most reduction in its activity and antithrombin was most resistant factor (Table 3).

---

**Table 2.** Inactivation of Model viruses using 0.1 µM concentration of MB and different illumination time \((n = 3)\).

| Model Virus (Mean titer) | Exposure Time (minutes) | Energy J/cm² | HSV  | VSV  | BVDV | Polio |
|-------------------------|-------------------------|--------------|------|------|------|-------|
|                         |                         |              | \(10^{7.28}\) | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| Initial titer           | 0.0*                    | 0            | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| FFP sample: 0 min       | 0.0*                    | 0            | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 15 min                  | 27                      | 10⁴-49       | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 30 min                  | 54                      | 10⁴-49       | \(10^{7.66}\) | \(10^{7.22}\) | \(10^{7.22}\) |
| 45 min                  | 81                      | 0.0*         | \(10^{7.66}\) | \(10^{7.22}\) | \(0.0*\) |
| 60 min                  | 108                     | 0.0*         | \(10^{7.66}\) | \(10^{7.22}\) | \(0.0*\) |

*NO CPE observed in any well
Table 3. FFP proteins activity evaluation after pathogen reduction with 1 µM MB and Illumination in 30 minutes at 627 nm (n = 3).

|                    | Before illumination | After 30 min illumination | Activity loss % | Normal range |
|--------------------|---------------------|---------------------------|-----------------|--------------|
| Factor V (%)       | 91.5                | 82.5                      | 11.0            | 60-130       |
| Factor VIII (%)    | 97.7                | 85.2                      | 11.4            | 60-150       |
| Fibrinogen (mg/ml) | 287.5               | 237.5                     | 12.1            | 200-400      |
| Antithrombin (%)   | 108                 | 104                       | 10.3            | 80-120       |

BVDV inactivation was demonstrated to be more sensitive to this protocol. Illumination for 30-45 minutes and in 1 µM concentration of MB was strong enough to inactivate most viruses. However, illumination for 60 minutes had no significant difference in pathogen reduction in compare with 45 minutes (p < 0.05). MB in 0.1 µM was not efficient, and so MB concentration is an important point. Fibrinogen had most reduction in this protocol that shows its sensitivity to MB and illumination but antithrombin is the most resistance one. Factor V and VIII activity reduction was near to Theraflex Methods (17). In spite of reduction in these factors,

Fig. 1. CPE of model viruses before and after inactivation using combination of MB and irradiation method.
they maintained in normal range.

Spring protocol uses fluorescent lamps illumination from one side and has no temperature control. In Theraflex Macotronic V® method sodium lamps from two sides are used. And also in the latest technology employed by Theraflex Macotronic B® LED employed in two sides. Our new device shows the outcome similar to the latest technology of MB based inactivation methods. In Both Theraflex and our new device temperature is monitored, and all three commercial protocols used MB in 1 µM as best final concentration (18, 19).

Achieving zero risk in chemotherapy remains the ultimate goal. This approach has not been met yet, but there are some promising results observed. Pathogen reduction by TMB, plasma is one additional critical factor to fulfill this aim. Eventually it is expected that with increasing clinical data and further methodological improvement, acceptance measure will rise, making pathogen reduction to become the standard routine procedure in many countries (19). This new designated and device needs more developments for commercialization.

REFERENCES

1. World Health Organization (WHO) technical Report, Series NO.924. 2004.
2. Au Buchon J. P. Update on the statue of pathogen inactivation methods, ISBT Science series 2011; 6: 181-188.
3. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion- transmitted infections. J Transl Med 2007; 5:25.
4. Rock G. A comparison of methods of pathogen inactivation of FFP, Vox Sang, 2011; 100: 169-178.
5. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19: 205-242.
6. Wallis C, Melnick JL. Photodynamic inactivation of animal viruses: a review. Photochemphotobiol 1965; 4: 159-170.
7. WHO, Guideline on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products, Geneva, 26-30 November 2001.
8. Seghatchian J, Kraladssri P. the quality of Methylene blue light treated FFP and cryopororecipitate. Transfuse Apheresis Sci, 2001; 25: 227-231.
9. Mohr H, Lambrecht B, Selz A. a photodynamic virus inactivation of blood components. Immunol Invest, 1995; 24: 73-85.
10. Solheim BG, Seghatchian J. update on pathogen reduction technology for therapeutic plasma: an overview. Transfuse Apher Sci 2006; 35: 83-90.
11. Lambrecht B, Mohr H, Knuver-Hope FJ, Shmith H. Photoinactivation of viruses in human fresh frozen plasma by henothiazine dyes in combination with visible light, Vox Sang, 1991; 60: 207-213.
12. Aghaei A, Pourfatollah A, et al. inactivation of virus in intravenous immunoglobulin G using solvent/ detergent treatment and pasteurization. Human Antibodies 2008; 17: 79-84.
13. B.W.J. Maltly and H.O. Kangro. Virology methods manual, quantitation of virus. Academic Press. ISBN 0-12 465-330-8, 1996.
14. Busch M, Kleinman S, Neo G. current and emerge infectious risks of blood transfusion. JAMA 2003; 289: 959-962.
15. Devta15. Jr., VT, Hellman S, Rosenberg SA, editors AIDS: Etiology, diagnosis, treatment and prevention, 3rd ed. Philadelphia, PA: Lippincot; 1992.
16. Schochet main G, AIDS testing. 2nd ed. New York, NY: springer verlag; 1994.
17. Williamson L,M, Cardigan R, Prowse C.V. Methylene blue treated fresh frozen plasma: what is its contribution to blood safety?, Transfusion 2003; 43: 1322-1329.
18. Rock G. A comparison of methods of pathogen inactivation of FFP, Vox Sang 2010; 100: 169-178.
19. Seghatchian J, SturflWG, Reichenberg S. Main properties of the THERAFLEX MB-system for pathogen reduction, Transfusion Med and Hemotherapy, pulished on line, 2011; 38: 000-000.